Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T19:57:00.839Z Has data issue: false hasContentIssue false

180 - Pneumocystis jirovecii (carinii)

from Part XXII - Specific organisms: fungi

Published online by Cambridge University Press:  05 April 2015

Shelley A. Gilroy
Affiliation:
Albany Medical College
Nicholas J. Bennett
Affiliation:
Temple University School of Medicine
David Schlossberg
Affiliation:
Temple University, Philadelphia
Get access

Summary

Background

Pneumocystis jirovecii (pronounced “yee-row-vet-zee”), formerly known as Pneumocystis carinii, is an opportunistic pathogen that causes pneumonia in the immunocompromised individual. The initials “PCP” stood for Pneumocystis carinii pneumonia but were kept for ease of use after the organism was renamed. Disease occurs when both cellular and humoral immunity are impaired. Serologic studies have shown that Pneumocystis has a worldwide distribution but the prevalence of antibodies to specific antigens varies among different geographic regions. PCP first came to attention when it caused interstitial pneumonia in severely malnourished and premature infants in Central and Eastern Europe during World War II. Prior to the acquired immunodeficiency syndrome (AIDS) epidemic in the 1980s, fewer than 100 cases were reported annually in the United States. PCP is one of several life-threatening opportunistic infections in patients with human immunodeficiency virus (HIV) infection worldwide and is still the most common AIDS-defining illness in patients with advanced HIV infection. The decline in the number of PCP cases in the United States occurred after the introduction of anti-pneumocystis prophylaxis in 1989 and highly active antiretroviral therapy (HAART) in 1992. In patients without HIV infection, the incidence of PCP has increased in those being treated with immunosuppressive and chemotherapeutic agents and in hematopoietic stem cell (HSCT) and solid organ transplant recipients.

The taxonomic classification of the Pneumocystis genus and the organism’s name has changed throughout the years. In the 1980s, biochemical analysis identified the organism as a unicellular fungus. Pneumocystis jirovecii is found in three distinct morphologic stages: the trophozoite, in which it often exists in clusters, the sporozoite (precystic form), and the cyst, which contains several intracystic bodies (spores). The cyst is the diagnostic form of P. jirovecii and stains with Giemsa, Papanicolau, and Grocott methenamine silver nitrate (GMS) and immunocytochemical techniques using monoclonal antibodies. Giemsa- and Papanicolau-stained smears show indirect evidence of P. jirovecii infection by the demonstration of foamy exudates in the form of alveolar casts.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bodro, M, Paterson, DL. Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?Clin Infect Dis. 2013;56(11):1621–1628.CrossRefGoogle ScholarPubMed
Gilroy, SA, Bennett, NJ. Pneumocystis pneumonia. Semin Respir Crit Care Med. 2011;32(6):775–782.CrossRefGoogle ScholarPubMed
McKinnell, JA, Canella, DF, Kunz, EW, et al. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis. 2012;14:510–518.CrossRefGoogle ScholarPubMed
Mocroft, A, Reiss, P, Kirk, O, et al. Is it safe to discontinue primary Pneumocystis jirovecii pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count < 200 cells/microL?Clin Infect Dis. 2010;51(5):611–619.Google Scholar
Sistek, CJ, Wordell, CJ, Hauptman, SP. Adjuvant corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS patients. Ann Pharmacother. 1992;26(9):1127–1133.CrossRefGoogle ScholarPubMed
Wazir, JF, Ansari, NA. Pneumocystis carinii infection. Arch Pathol Lab Med. 2004;128:1023–1027.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×